RxDoctor Payments Data

Amy Almany

Family · Abingdon, VANPI 1730699505

Payments from drug & device makers

$9,586in general payments, 2019–2025

Across 449 payments — averaging $21.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • GSK$812
  • Johnson & Johnson$669
  • Lilly USA, LLC$550
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$9,50499%
  • Education$821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,586 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$111,743
Medicare patients
264
Services billed
1,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban182$155,199
OzempicSemaglutide80$95,328
Dupixent SyringeDupilumab18$76,539
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$59,148
FarxigaDapagliflozin Propanediol81$57,102
TrulicityDulaglutide46$52,747
XareltoRivaroxaban52$43,379
XifaxanRifaximin11$37,617
JardianceEmpagliflozin27$30,050
Breo ElliptaFluticasone/Vilanterol27$22,730
Repatha SyringeEvolocumab29$22,700
LinzessLinaclotide41$21,221
AbrysvoRsv Vacc, Pref A And Pref B/Pf65$20,827
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen513$16,096
Spiriva RespimatTiotropium Bromide17$14,960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$367$176,027247 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Anoro Ellipta$812$106,263167 claims
Novo NordiskOzempic$1,268$95,32880 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$2,149$78,454121 claims
Lilly USA, LLCTrulicity$550$52,74746 claims
Boehringer IngelheimJardiance, Spiriva Respimat$69$45,01044 claims
Johnson & JohnsonXarelto$669$43,37952 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$72$37,61711 claims
AbbVieLinzess, Synthroid$160$27,984141 claims
NovartisEntresto$259$11,27415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Abingdon

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →